The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Targeting non-coding RNAs to overcome cancer therapy resistance
Open accessAbstract
It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts, are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are widely appreciated as pervasive regulators of multiple cancer hallmarks such as proliferation, apoptosis, invasion, metastasis, and genomic instability. Despite recent discoveries in cancer therapy, resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy continue to be a major setback. Recent studies have shown that ncRNAs also play a major role in resistance to different cancer therapies by rewiring essential signaling pathways. In this review, we present the intricate mechanisms through which dysregulated ncRNAs control resistance to the four major types of cancer therapies. We will focus on the current clinical implications of ncRNAs as biomarkers to predict treatment response (intrinsic resistance) and to detect resistance to therapy after the start of treatment (acquired resistance). Furthermore, we will present the potential of targeting ncRNA to overcome cancer treatment resistance, and we will discuss the challenges of ncRNA-targeted therapy—especially the development of delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Xiao, Y., Yurievich, U. A., & Yosypovych, S. V. (2017) · Oncotarget · doi:10.18632/oncotarget.20487 · Cited by 55
RetractedPu, Y., Yi, Q., Zhao, F., Wang, H., Cai, W., & Cai, S. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0340-3 · Cited by 52
RetractedArzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Circular RNAs are a large class of animal RNAs with regulatory potency
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S. D., Gregersen, L. H., Munschauer, M., et al. (2013) · Nature · doi:10.1038/nature11928 · Cited by 7,990 · cited 1×
“being able to bind tens of miRNA molecules and inhibit their function.(31,32) However, only a few circRNAs are capable of binding multiple miRNA molecules.”
BackgroundNatural RNA circles function as efficient microRNA sponges
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K., & Kjems, J. (2013) · Nature · doi:10.1038/nature11993 · Cited by 7,985
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., Guernec, G., Martin, D., Merkel, A., Knowles, D. G., et al. (2012) · Genome Research · doi:10.1101/gr.132159.111 · Cited by 5,061
miRBase: from microRNA sequences to function
Kozomara, A., Birgaoanu, M., & Griffiths-Jones, S. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1141 · Cited by 4,843
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“Antagomirs function by complementary binding to miRNAs, thus preventing their interaction with their target genes.(140) Locked nucleic acid is another commonly used chemical modification in anti-miRNA ASOs.”
MethodTumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846 · cited 1×
“Resistance to chemotherapy Many factors can induce chemotherapy resistance, but probably the most important is tumor heterogeneity.(48) For intrinsic resistance, intertumoral heterogeneity plays a crucial role, and the genetic variability (germline variations) between patients Targeting non-coding RNAs to overcome can…”
BackgroundBartel, D. P. (2018) · Cell · doi:10.1016/j.cell.2018.03.006 · Cited by 3,751
Unique features of long non-coding RNA biogenesis and function
Quinn, J. J., & Chang, H. Y. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.10 · Cited by 3,672
Liposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019055108 · Cited by 3,294
Ji, P., Diederichs, S., Wang, W., Böing, S., Metzger, R., Schneider, P. M., Tidow, N., Brandt, B., Buerger, H., Bulk, E., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206928 · Cited by 2,189
Endogenous microRNA sponges: evidence and controversy
Thomson, D. W., & Dinger, M. E. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.20 · Cited by 2,185
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · cited 1×
“Unfortunately, not all treated patients experience effective responses.(67) Mechanisms of resistance to immune checkpoint therapy can be divided into (1) deficient anti-tumor T cell production, (2) poor anti-tumor T cell effector function, and (3) impaired development of T cell memory.”
BackgroundMicroRNA biogenesis pathways in cancer
Lin, S., & Gregory, R. I. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3932 · Cited by 2,112
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Cell-Type Specific Features of Circular RNA Expression
Salzman, J., Chen, R. E., Olsen, M. N., Wang, P. L., & Brown, P. O. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003777 · Cited by 1,950
Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells
Mittelbrunn, M., Gutiérrez-Vázquez, C., Villarroya-Beltri, C., González, S., Sánchez-Cabo, F., González, M. Á., Bernad, A., & Sánchez-Madrid, F. (2011) · Nature Communications · doi:10.1038/ncomms1285 · Cited by 1,769
Role of MicroRNAs in Plant and Animal Development
Carrington, J. C., & Ambros, V. (2003) · Science · doi:10.1126/science.1085242 · Cited by 1,767
The biogenesis and emerging roles of circular RNAs
Chen, L.-L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.32 · Cited by 1,743
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
The Endothelial-Specific MicroRNA miR-126 Governs Vascular Integrity and Angiogenesis
Wang, S., Aurora, A. B., Johnson, B. A., Qi, X., McAnally, J., Hill, J. A., Richardson, J. A., Bassel-Duby, R., & Olson, E. N. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.07.002 · Cited by 1,617
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551 · cited 2×
“Therapeutic modalities targeting ncRNAs are usually developed with one of two strategies: the first is to inhibit the specific ncRNA molecule if it is overexpressed, and the second is to overexpress a tumor suppressor ncRNA.(138) A schematic overview of the ncRNA therapeutic strategies and delivery mechanisms is depic…”
BackgroundMicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response
Fabbri, M., Paone, A., Calore, F., Galli, R., Gaudio, E., Santhanam, R., Lovat, F., Fadda, P., Mao, C., Nuovo, G. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209414109 · Cited by 1,434
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · cited 1×
“Mechanisms of resistance to immune checkpoint therapy can be divided into (1) deficient anti-tumor T cell production, (2) poor anti-tumor T cell effector function, and (3) impaired development of T cell memory.(68) Additionally, resistance to ICIs was linked to other immune cells such as natural killer (NK) cells and…”
BackgroundMarcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176
Qu, L., Ding, J., Chen, C., Wu, Z.-J., Liu, B., Gao, Y., Chen, W., Liu, F., Sun, W., Li, X.-F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.004 · Cited by 1,117
MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease
Kordelas, L., Rebmann, V, Ludwig, A.-K., Radtke, S., Ruesing, J., Doeppner, T. R., Epple, M., Horn, P. A., Beelen, D. W., & Giebel, B. (2014) · Leukemia · doi:10.1038/leu.2014.41 · Cited by 1,084
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Hong, D. S., Kang, Y.-K., Borad, M., Sachdev, J., Ejadi, S., Lim, H. Y., Brenner, A. J., Park, K., Lee, J.-L., Kim, T.-Y., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0802-1 · Cited by 975
Biomarkers: Potential uses and limitations
Mayeux, R. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.182 · Cited by 916
Noncoding RNA NORAD Regulates Genomic Stability by Sequestering PUMILIO Proteins
Lee, S., Kopp, F., Chang, T.-C., Sataluri, A., Chen, B., Sivakumar, S., Yu, H., Xie, Y., & Mendell, J. T. (2016) · Cell · doi:10.1016/j.cell.2015.12.017 · Cited by 897
Self-citationHenry, N. L., & Hayes, D. F. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.010 · Cited by 849
An unconventional role for miRNA: let-7 activates toll-like receptor 7 and causes neurodegeneration
Lehmann, S. M., Krüger, C., Park, B., Derkow, K., Rosenberger, K., Baumgart, J., Trimbuch, T., Eom, G., Hinz, M., Kaul, D., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3113 · Cited by 786
Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity
Du, W. W., Fang, L., Yang, W., Wu, N., Awan, F. M., Yang, Z., & Yang, B. B. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2016.133 · Cited by 776
MicroRNA sponges: Progress and possibilities
Ebert, M. S., & Sharp, P. A. (2010) · RNA · doi:10.1261/rna.2414110 · Cited by 762
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas
Calin, G. A., Liu, C.-G., Ferracin, M., Hyslop, T., Spizzo, R., Sevignani, C., Fabbri, M., Cimmino, A., Lee, E. J., Wojcik, S. E., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.027 · Cited by 719
Self-citationGalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics
Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711
Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function
Pang, K. C., Frith, M. C., & Mattick, J. S. (2006) · Trends in Genetics · doi:10.1016/j.tig.2005.10.003 · Cited by 656
The Promise of MicroRNA Replacement Therapy
Bader, A. G., Brown, D., & Winkler, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2010 · Cited by 617
Schrock, A. B., Ouyang, C., Sandhu, J., Sokol, E., Jin, D., Ross, J. S., Miller, V. A., Lim, D., Amanam, I., Chao, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz134 · Cited by 617
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913147 · Cited by 608
Ling, H., Spizzo, R., Atlasi, Y., Nicoloso, M., Shimizu, M., Redis, R. S., Nishida, N., Gafà, R., Song, J., Guo, Z., et al. (2013) · Genome Research · doi:10.1101/gr.152942.112 · Cited by 602
Self-citationZhang, P.-F., Gao, C., Huang, X.-Y., Lu, J.-C., Guo, X.-J., Shi, G.-M., Cai, J.-B., & Ke, A.-W. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01222-5 · Cited by 593
Xu, C., Chen, Y.-P., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G.-Q., Li, W.-F., Mao, Y.-P., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 558
Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., de Braud, F., Rolfo, C., Ahn, M.-J., Wolf, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30690-4 · Cited by 528
Molecular Mechanisms and Biological Functions of siRNA
Department of Biology, D. B., Dana, H., Chalbatani, G. M., Mahmoodzadeh, H., Gharagouzlo, E., Cancer Research Center, C. I. O. I., Karimloo, R., Department of Medicine, Z. M. S., Rezaiean, O., Moradzadeh, A., et al. (2017) · International Journal of Biomedical Science · doi:10.59566/ijbs.2017.13048 · Cited by 505
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1
Xu, J., Ji, L., Liang, Y., Wan, Z., Zheng, W., Song, X., Gorshkov, K., Sun, Q., Lin, H., Zheng, X., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00375-5 · Cited by 495
Huang, X., Li, Z., Zhang, Q., Wang, W., Li, B., Wang, L., Xu, Z., Zeng, A., Zhang, X., Zhang, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0969-3 · Cited by 476
Self-citationCancer Stem Cells and Drug Resistance: The Potential of Nanomedicine
Vinogradov, S., & Wei, X. (2012) · Nanomedicine · doi:10.2217/nnm.12.22 · Cited by 474
Clinical utility of circulating non-coding RNAs — an update
Anfossi, S., Babayan, A., Pantel, K., & Calin, G. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0035-x · Cited by 450
Self-citationLu, Y., Zhao, X., Liu, Q., Li, C., Graves-Deal, R., Cao, Z., Singh, B., Franklin, J. L., Wang, J., Hu, H., et al. (2017) · Nature Medicine · doi:10.1038/nm.4424 · Cited by 425
Hu, G., Tang, Q., Sharma, S., Yu, F., Escobar, T. M., Muljo, S. A., Zhu, J., & Zhao, K. (2013) · Nature Immunology · doi:10.1038/ni.2712 · Cited by 406
Londin, E., Loher, P., Telonis, A. G., Quann, K., Clark, P., Jing, Y., Hatzimichael, E., Kirino, Y., Honda, S., Lally, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420955112 · Cited by 404 · cited 1×
“Many additional miRNAs, mostly with tissue-specific distribution, have also been discovered.(9) Most of these genes are conserved between species.”
BackgroundMolecular Mechanisms of Antisense Oligonucleotides
Crooke, S. T. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0656 · Cited by 396
Determinants and clinical implications of chromosomal instability in cancer
Sansregret, L., Vanhaesebroeck, B., & Swanton, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.198 · Cited by 396
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367 · cited 4×
“An additional element associated with ICI resistance is MDSCs, high levels of which may be associated with resistance to ICIs.(70) Huber et al.”
BackgroundInfluentialShort hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown
Taxman, D. J., Moore, C. B., Guthrie, E. H., & Huang, M. T.-H. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-657-3_10 · Cited by 365
Long Noncoding RNAs as Biomarkers in Cancer
Bolha, L., Ravnik-Glavač, M., & Glavač, D. (2017) · Disease Markers · doi:10.1155/2017/7243968 · Cited by 365
Xia, X., Li, X., Li, F., Wu, X., Zhang, M., Zhou, H., Huang, N., Yang, X., Xiao, F., Liu, D., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1056-5 · Cited by 354
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression
Hu, Q., Ye, Y., Chan, L.-C., Li, Y., Liang, K., Lin, A., Egranov, S. D., Zhang, Y., Xia, W., Gong, J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0400-7 · Cited by 353
Zhang, H.-G., & Grizzle, W. E. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.09.027 · Cited by 352
MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges
Lan, H., Lu, H., Wang, X., & Jin, H. (2015) · BioMed Research International · doi:10.1155/2015/125094 · Cited by 330
Global Positioning System: Understanding Long Noncoding RNAs through Subcellular Localization
Carlevaro-Fita, J., & Johnson, R. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.02.008 · Cited by 318
Lipid-based carriers of microRNAs and intercellular communication
Vickers, K. C., & Remaley, A. T. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328350a425 · Cited by 314
He, W., Liang, B., Wang, C., Li, S., Zhao, Y., Huang, Q., Liu, Z., Yao, Z., Wu, Q., Liao, W., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0747-0 · Cited by 304
An RNA Processing Activity That Debranches RNA Lariats
Ruskin, B., & Green, M. R. (1985) · Science · doi:10.1126/science.2990042 · Cited by 283
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0033 · Cited by 268 · cited 1×
“The latter agent is designed for treating hereditary transthyretin-mediated amyloidosis.(15,155) A stimulus-responsive nanoparticle delivery system that releases the target drug in a stimuli-responsive manner (triggered by enzymes, pH, glutathione, specific temperature, hypoxia, ROS, etc.”
BackgroundmiR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells
Lechman, E. R., Gentner, B., Ng, S. W. K., Schoof, E. M., van Galen, P., Kennedy, J. A., Nucera, S., Ciceri, F., Kaufmann, K. B., Takayama, N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.011 · Cited by 268
Chen, J., Jin, R., Zhao, J., Liu, J., Ying, H., Yan, H., Zhou, S., Liang, Y., Huang, D., Liang, X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.019 · Cited by 251
Huber, V., Vallacchi, V., Fleming, V., Hu, X., Cova, A., Dugo, M., Shahaj, E., Sulsenti, R., Vergani, E., Filipazzi, P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98060 · Cited by 250
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Ellis, L. M., & Hicklin, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1070 · Cited by 248
Hamano, R., Miyata, H., Yamasaki, M., Kurokawa, Y., Hara, J., Moon, J. H., Nakajima, K., Takiguchi, S., Fujiwara, Y., Mori, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2532 · Cited by 243
Zhang, X., Xu, L., & Wang, F. (2017) · Cell Biology International · doi:10.1002/cbin.10826 · Cited by 241
Ottosen, S., Parsley, T. B., Yang, L., Zeh, K., van Doorn, L.-J., van der Veer, E., Raney, A. K., Hodges, M. R., & Patick, A. K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04220-14 · Cited by 230
Huang, X.-Y., Zhang, P.-F., Wei, C.-Y., Peng, R., Lu, J.-C., Gao, C., Cai, J.-B., Yang, X., Fan, J., Ke, A.-W., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01213-6 · Cited by 222
Drayton, R. M., Dudziec, E., Peter, S., Bertz, S., Hartmann, A., Bryant, H. E., & Catto, J. W. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2805 · Cited by 220
Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility
Dragomir, M. P., Kopetz, S., Ajani, J. A., & Calin, G. A. (2020) · Gut · doi:10.1136/gutjnl-2019-318279 · Cited by 211
Self-citationSnapShot: Unconventional miRNA Functions
Dragomir, M. P., Knutsen, E., & Calin, G. A. (2018) · Cell · doi:10.1016/j.cell.2018.07.040 · Cited by 207
Self-citationIntrinsic and Acquired Drug Resistance in Malignant Tumors
Lippert, T. H., Ruoff, H. J., & Volm, M. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1296504 · Cited by 202
Stimulus-Responsive Macromolecules and Nanoparticles for Cancer Drug Delivery
MacEwan, S. R., Callahan, D. J., & Chilkoti, A. (2010) · Nanomedicine · doi:10.2217/nnm.10.50 · Cited by 201
Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies
Pardini, B., Sabo, A. A., Birolo, G., & Calin, G. A. (2019) · Cancers · doi:10.3390/cancers11081170 · Cited by 199
Self-citationMiR-138 exerts anti-glioma efficacy by targeting immune checkpoints
Wei, J., Nduom, E. K., Kong, L.-Y., Hashimoto, Y., Xu, S., Gabrusiewicz, K., Ling, X., Huang, N., Qiao, W., Zhou, S., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov292 · Cited by 197
Self-citationExosomal lncRNAs as new players in cell-to-cell communication
Dragomir, M., Chen, B., & Calin, G. A. (2018) · Translational Cancer Research · doi:10.21037/tcr.2017.10.46 · Cited by 194
Self-citationSantoni-Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 194
Classical and noncanonical functions of miRNAs in cancers
Dragomir, M. P., Knutsen, E., & Calin, G. A. (2022) · Trends in Genetics · doi:10.1016/j.tig.2021.10.002 · Cited by 191
Self-citationAllele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2
Redis, R. S., Vela, L. E., Lu, W., Ferreira de Oliveira, J., Ivan, C., Rodriguez-Aguayo, C., Adamoski, D., Pasculli, B., Taguchi, A., Chen, Y., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.01.015 · Cited by 181
Self-citationExtracellular communication via microRNA: lipid particles have a new message
Rayner, K. J., & Hennessy, E. J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r034991 · Cited by 164
Molina, A. M., Lin, X., Korytowsky, B., Matczak, E. M., Lechuga, M. J., Wiltshire, R., & Motzer, R. J. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.021 · Cited by 162
Kjersem, J. B., Ikdahl, T., Lingjærde, O. C., Guren, T. K., Tveit, K. M., & Kure, E. H. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.09.001 · Cited by 157
Pihan, G. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00277 · Cited by 155
Alix‐Panabières, C. (2020) · Nature · doi:10.1038/d41586-020-00844-5 · Cited by 151
Decrypting noncoding RNA interactions, structures, and functional networks
Fabbri, M., Girnita, L., Varani, G., & Calin, G. A. (2019) · Genome Research · doi:10.1101/gr.247239.118 · Cited by 147
Self-citationAntibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
Dugal‐Tessier, J., Thirumalairajan, S., & Jain, N. F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040838 · Cited by 144
CRISPR/Cas9-mediated noncoding RNA editing in human cancers
Yang, J., Meng, X., Pan, J., Jiang, N., Zhou, C., Wu, Z., & Gong, Z. (2017) · RNA Biology · doi:10.1080/15476286.2017.1391443 · Cited by 141
Circular RNAs in Cancer – Lessons Learned From microRNAs
Dragomir, M. P., & Călin, G. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00179 · Cited by 141
Self-citationPajic, M., Froio, D., Daly, S., Doculara, L., Millar, E. K. A., Graham, P., Drury, A., Steinmann, A. M., de Bock, C. E., Boulghourjian, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3105 · Cited by 140
Rigoutsos, I., Huynh, T., Miranda, K. C., Tsirigos, A., McHardy, A. C., & Platt, D. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601688103 · Cited by 136
The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling
Chen, B., Dragomir, M. P., Fabris, L., Bayraktar, R., Knutsen, E., Liu, X., Tang, C., Li, Y., Shimura, T., Ivković, T. C., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.08.018 · Cited by 134
Self-citationInterspecies regulation of microRNAs and their targets
Ha, M., Pang, M., Agarwal, V., & Chen, Z. J. (2008) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2008.03.004 · Cited by 128
Xu, W., Liu, J.-P., Feng, J., Zhu, C.-P., Yang, Y., Zhou, W., Ding, J., Huang, C., Cui, Y., Ding, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318830 · Cited by 123
Chevli, K., Duff, M., Walter, P., Yu, C., Capuder, B., Elshafei, A., Malczewski, S., Kattan, M. W., & Jones, J. S. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.12.005 · Cited by 121
Noncoding RNA s and immune checkpoints—clinical implications as cancer therapeutics
Smolle, M. A., Calin, H. N., Pichler, M., & Călin, G. A. (2017) · FEBS Journal · doi:10.1111/febs.14030 · Cited by 121
Hansen, T. F., Carlsen, A. L., Heegaard, N. H. H., Sørensen, F. B., & Jakobsen, A. K. M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.652 · Cited by 117
N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration
Rigoutsos, I., Lee, S. K., Nam, S. Y., Anfossi, S., Pasculli, B., Pichler, M., Yi, J., Rodriguez‐Aguayo, C., Telonis, A. G., Rossi, S., et al. (2017) · Genome biology · doi:10.1186/s13059-017-1224-0 · Cited by 115
Guo, Z., Wang, Y.-H., Xu, H., Yuan, C., Zhou, H., Huang, W., Wang, H., & Zhang, W. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03302-2 · Cited by 114
SERS liquid biopsy: An emerging tool for medical diagnosis
Moisoiu, V., Iancu, Ș. D., Ştefancu, A., Moisoiu, T., Pardini, B., Dragomir, M. P., Crişan, N., Avram, L., Crișan, D., Andraș, I., et al. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.112064 · Cited by 113
Self-citationScreening for Small-Molecule Modulators of Long Noncoding RNA-Protein Interactions Using AlphaScreen
Fatemi, R. P., Salah-Uddin, S., Modarresi, F., Khoury, N., Wahlestedt, C., & Faghihi, M. A. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115594187 · Cited by 109
Zhang, Y., Zheng, L., Ding, Y., Li, Q., Wang, R., Liu, T., Sun, Q., Yang, H., Peng, S., Wang, W., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.04.007 · Cited by 109
Self-citationA Single Cell but Many Different Transcripts: A Journey into the World of Long Non-Coding RNAs
Alessio, E., Bonadio, R. S., Buson, L., Chemello, F., & Cagnin, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010302 · Cited by 109
The role of microRNAs in cancers of the upper gastrointestinal tract
Song, S., & Ajani, J. A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.210 · Cited by 106
Small molecules targeting microRNA for cancer therapy: Promises and obstacles
Wen, D., Danquah, M. K., Chaudhary, A., & Mahato, R. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.011 · Cited by 104
Ekin, A., Karataş, Ö. F., Çulha, M., & Özen, M. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2810 · Cited by 99
Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer
Pichler, M., Rodriguez‐Aguayo, C., Nam, S. Y., Dragomir, M. P., Bayraktar, R., Anfossi, S., Knutsen, E., Ivan, C., Fuentes‐Mattei, E., Lee, S. K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318903 · Cited by 99
Self-citationResistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Neel, D. S., & Bivona, T. G. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0007-0 · Cited by 98
Hoppe, R., Achinger-Kawecka, J., Winter, S., Fritz, P., Lo, W., Schroth, W., & Brauch, H. B. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.145 · Cited by 95
Rasmussen, M. H., Lyskjær, I., Jersie-Christensen, R., Tarpgaard, L. S., Primdal-Bengtson, B., Nielsen, M. M., Pedersen, J. S., Hansen, T. P., Hansen, F., Olsen, J. V., et al. (2016) · Nature Communications · doi:10.1038/ncomms12436 · Cited by 93
Using microRNA Networks to Understand Cancer
Dragomir, M. P., Mafra, A. C. P., Dias, S. M. G., Vasilescu, C., & Călin, G. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071871 · Cited by 93
Self-citationYuan, Y., Liao, H., Pu, Q., Ke, X., Hu, X., Ma, Y., Luo, X., Jiang, Q., Gong, Y., Wu, M., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0182-2 · Cited by 93
Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment
Omar, H. A., El-Serafi, A. T., Hersi, F., Arafa, E. A., Zaher, D. M., Madkour, M. I., Arab, H. H., & Tolba, M. F. (2019) · FEBS Journal · doi:10.1111/febs.15000 · Cited by 90
Shukuya, T., Ghai, V., Amann, J. M., Okimoto, T., Shilo, K., Kim, T., Wang, K., & Carbone, D. P. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.022 · Cited by 89
Shaath, H., Vishnubalaji, R., Elango, R., Khattak, S., & Alajez, N. M. (2021) · Cell Death Discovery · doi:10.1038/s41420-020-00383-y · Cited by 89
Caporali, S., Amaro, A. A., Levati, L., Alvino, E., Lacal, P. M., Mastroeni, S., Ruffini, F., Bonmassar, L., Cappellini, G. C. A., Felli, N., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1238-4 · Cited by 88
Rasmussen, M. H., Jensen, N. F., Tarpgaard, L. S., Qvortrup, C., Rømer, M. U., Stenvang, J., Hansen, T. P., Christensen, L. L., Lindebjerg, J., Hansen, F., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.016 · Cited by 87
Liu, R., Zeng, Y., Zhou, C., Wang, Y., Li, X., Liu, Z., Chen, X., Zhang, W., & Zhou, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-00050-w · Cited by 85
Xiong, Y., Sun, F., Dong, P., Watari, H., Yue, J., Yu, M.-F., Lan, C., Wang, Y., & Ma, Z.-B. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0520-6 · Cited by 85
Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy
Zhang, J., Zhang, K., Bi, M., Jiao, X., Zhang, D., & Dong, Q. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000049 · Cited by 81
Li, L., Shang, J., Zhang, Y., Liu, S., Peng, Y., Zhou, Z., Pan, H., Wang, X., Chen, L., & Zhao, Q. (2017) · Oncology Reports · doi:10.3892/or.2017.5828 · Cited by 81
FuncPEP: A Database of Functional Peptides Encoded by Non-Coding RNAs
Dragomir, M. P., Manyam, G. C., Ott, L. F., Berland, L., Knutsen, E., Ivan, C., Lipovich, L., Broom, B. M., & Călin, G. A. (2020) · Non-Coding RNA · doi:10.3390/ncrna6040041 · Cited by 78
Self-citationMiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review
Xu, W., Hua, Y.-T., Deng, F., Wang, D., Wu, Y. F., Zhang, W., & Tang, J. (2020) · Cancer Science · doi:10.1111/cas.14517 · Cited by 71
Jia, Z., Gong, Y. Q., Pi, Y., Liu, X., Gao, L., Kang, L., Wang, J., Yang, F., Tang, J., Lu, W., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00709 · Cited by 68
Self-citationShah, M., Ferracin, M., Pileczki, V., Chen, B., Redis, R. S., Fabris, L., Zhang, X., Ivan, C., Shimizu, M., Rodriguez‐Aguayo, C., et al. (2018) · Genome Research · doi:10.1101/gr.225128.117 · Cited by 68
Self-citationMicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia
Lim, E. L., Trinh, D. L. N., Ries, R. E., Wang, J., Gerbing, R. B., Ma, Y. P., Topham, J. T., Hughes, M., Pleasance, E., Mungall, A. J. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7451 · Cited by 61
Pulling the plug on a cancer cell by eliminating XIAP with AEG35156
LaCasse, E. C. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.06.015 · Cited by 57
Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics
Zhou, T., Kim, Y., & MacLeod, A. R. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3378-5_16 · Cited by 54
Zhao, Q., Cao, J., Wu, Y., Liu, X., Han, J., Huang, X., Jiang, L., Hou, X., Mao, W., & Ling, Z. (2015) · Europe PMC (PubMed Central) · Cited by 50
Zhang, Y., Li, B., Bai, Q., Wang, P., Wei, G., Li, Z., Li, H., Qin, T., Zhou, J., Huang, Q., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00492-9 · Cited by 50
McGuire, A., Casey, M., Waldron, R. M., Heneghan, H., Kalinina, O., Holian, E., McDermott, A. M., Lowery, A., Newell, J., Dwyer, R. M., et al. (2020) · Cancers · doi:10.3390/cancers12071820 · Cited by 44
Tumor-Agnostic Drug Development
Offin, M. D., Liu, D., & Drilon, A. E. D. C. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200831 · Cited by 43
Key questions about the checkpoint blockade-are microRNAs an answer?
Dragomir, M. P., Chen, B., Fu, X., & George, A. C. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0006 · Cited by 42
Self-citationLü, H., Lu, S., Yang, D., Zhang, L., Ye, J., Mao, L., & Hu, W. (2019) · Bioscience Reports · doi:10.1042/bsr20181374 · Cited by 42
MiR-106a: Promising biomarker for cancer
Pan, Y., Zhuang, Y., Zheng, J., & Pei, D. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.042 · Cited by 40
New Dancing Couple: PD ‐L1 and Micro RNA
Grenda, A., & Krawczyk, P. A. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12577 · Cited by 40
Zhu, W., Liu, M., Fan, Y., Ma, F., Xu, N., & Xu, B. (2018) · Cancer Medicine · doi:10.1002/cam4.1723 · Cited by 40
Pisignano, G., Napoli, S., Magistri, M., Mapelli, S. N., Pastori, C., Marco, S. D., Civenni, G., Albino, D., Enriquez, C., Allegrini, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15622 · Cited by 39
Zhen, S., Lu, J., Chen, W., Zhao, L., & Xu, L. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.048 · Cited by 39
Understanding the Genomic Ultraconservations: T-UCRs and Cancer
Fabris, L., & Călin, G. A. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.04.004 · Cited by 34
Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia
Aberuyi, N., Rahgozar, S., Ghodousi, E. S., & Ghaedi, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01496 · Cited by 34
Barth, D. A., Drulă, R., Ott, L. F., Fabris, L., Slabý, O., Călin, G. A., & Pichler, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00828 · Cited by 34
Zeng, Y., Wang, G., Zhou, C., Zhang, H., Sun, H., Zhang, W., Zhou, H., Liu, R., & Zhu, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00574 · Cited by 30
Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myeloma
Bai, Y., & Su, X. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13459 · Cited by 30
MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma
Lv, Y., Huang, Z., Lin, Y., Fang, Y., Chen, Z., Pan, L., Zhang, Y., & Xu, Z. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629260 · Cited by 29
Jin, J., Guo, Y., Dong, X., Liu, J., & He, Y. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.06.022 · Cited by 28
Ferrando, L., Cirmena, G., Garuti, A., Scabini, S., Grillo, F., Mastracci, L., Isnaldi, E., Marrone, C., Gonella, R., Murialdo, R., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226595 · Cited by 27
Meyer, M., Paquet, A. C., Arguel, M., Peyre, L., Gomes-Pereira, L. C., Lebrigand, K., Mograbi, B., Brest, P., Waldmann, R., Barbry, P., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.08.019 · Cited by 27
Sudo, K., Kato, K., Matsuzaki, J., Takizawa, S., Aoki, Y., Shoji, H., Iwasa, S., Honma, Y., Takashima, A., Sakamoto, H., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz146 · Cited by 26
Robak, P. J., Dróźdż, I., Jarych, D., Mikulski, D., Węgłowska, E., Siemieniuk‐Ryś, M., Misiewicz, M., Stawiski, K., Fendler, W. M., Szemraj, J., et al. (2020) · Cancers · doi:10.3390/cancers12092569 · Cited by 26
Garc�a‐Garc�a, F., Salinas-Vera, Y. M., Garc�a‐V�zquez, R., Marchat, L. A., Rodriguez-Cuevas, S. A., L�pez‐Gonz�lez, J., Carlos‐Reyes, �., Ramos‐Payán, R., Aguilar‐Medina, M., Pérez‐Plasencia, C., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7102 · Cited by 25
Du, W., Sun, L., Liu, T., Zhu, J., Zeng, Y., Zhang, Y., Wang, X., Liu, Z., & Huang, J. (2020) · Oncology Reports · doi:10.3892/or.2020.7579 · Cited by 25
miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1
Tan, W., Lin, Z., Chen, X., Li, W., Zhu, S., Wei, Y., Huo, L., Chen, Y., & Shang, C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-2081 · Cited by 25
MicroRNA-21 contributes to the discrimination of chemoresistance in metastatic gastric cancer
Qi, M., Liu, D., & Zhang, S. (2017) · Cancer Biomarkers · doi:10.3233/cbm-161732 · Cited by 22
Wang, X., Jin, N., Wang, Q., et al. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00240 · Cited by 20
The non‐coding RNome after splenectomy
Dragomir, M. P., Tudor, Ș., Okubo, K., Shimizu, M., Chen, M., Giza, D. E., He, W. R., Ivan, C., Călin, G. A., & Vasilescu, C. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14664 · Cited by 14
Self-citationDing, C., Shan, Z., Li, M., Xia, Y., & Jin, Z. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s300095 · Cited by 13
An miRNA signature associated with tumor mutation burden in endometrial cancer
Zhou, H., Chen, L., Qin, M., Lei, Y.-J., Li, T., Li, H.-R., & Cheng, X. (2020) · Bioscience Reports · doi:10.1042/bsr20203398 · Cited by 10
Xia, Y., Wang, Q., Huang, X., Yin, X.-H., Song, J., Ke, Z., & Duan, X.-F. (2020) · BioMed Research International · doi:10.1155/2020/1686480 · Cited by 10
Rinnerthaler, G., Gampenrieder, S. P., Hackl, H., Steiner, M. J., Monzo-Fuentes, C., Melchardt, T., Magnes, T., Huemer, F., Westphal, T., Hufnagl, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061663 · Cited by 9
Yang, D., Yu, J., Han, B., Sun, Y., Mo, S., & Hu, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.618313 · Cited by 9
Bulibu, J., Wang, W. T., Tang, Y., Li, N., & Keyoumu, S. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0366-4 · Cited by 8
Cited by
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
Ismail, N. H., Mussa, A., Al-Khreisat, M. J., Mohamed Yusoff, S., Husin, A., Al-Jamal, H. A. N., Johan, M. F., & Islam, M. A. (2023) · Non-Coding RNA · doi:10.3390/ncrna9060068 · Cited by 29
Metadata
- Authors
- Chen, B., Dragomir, M. P., Yang, C., Li, Q., Horst, D., & Calin, G. A.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2022-04-13
- Volume
- 7
- Issue
- 1
- Pages
- 121-121
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4223456024
- Cited by
- 435
- References
- 173
- FWCI
- 30.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.